Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT04340908
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Sponsor
- Hongchang Guo
- Registry
-
NCT04340908
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04340908. Randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-06-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Cardiac Surgery
- Intervention (Drug)
- Dapagliflozin 10 MG
- Intervention (Drug)
- Placebos
- Lead sponsor
- Hongchang Guo
Record details
- Record id
cardio:ct-nct04340908- Content hash
3353fcc1548755ebbe1b9c95832b3e34abb8e7d9390510b8439e112851866a12